Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 5 minute read Pharma Industry News Ultragenyx Pharmaceutical faces shareholder litigation risks after Orbit study update triggers stock plunge Ultragenyx faces legal probe and investor scrutiny after a 25% stock drop tied to delayed Phase 3 Orbit study data for UX143. Learn what analysts expect next. byPallavi MadhirajuJuly 19, 2025